3 results
The objective of this open label phase IIa trial is to evaluate the efficacy and tolerability of a once a week dose of 200 mg R126638, for a maximum of 12 weeks, for the treatment of toenail onychomycosis.
Primary Objective* To evaluate the antitumor efficacy of PO single agent CO-1686, as measured by ORR, when administered to patients with EGFR mutated, centrally confirmed T790M positive and T790M negative advanced NSCLC after tumor progression on 1…
The overall purpose of this trial is to assess the efficacy on weight loss and maintenance, and tolerability of four different doses of BI 456906 compared to placebo in patients with obesity or overweight (BMI >= 27kg/m2), without type 1 or…